Research, Science & development
-
Austrian researchers identify potential immunotherapy target for CALR-mutant blood cancers
The international research team found that natural killer (NK) cells in patients with mutations in the calreticulin (CALR) gene retain much of their ability to attack abnormal cells.
-
Teva terminates mid-stage trial of Emrusolmin in patients with multiple system atrophy
The oral drug was being evaluated in adults with MSA, a rare and progressive neurodegenerative disorder that affects movement, coordination and balance.
-
MOKAD strengthens translational cancer research collaboration across Türkiye, Europe
The association also promotes research with potential for practical applications, including developing new knowledge, technologies, and products that could support cancer diagnosis and treatment.
-
HighTide Therapeutics presents HTD1801 results for polycystic kidney disease at ASN Kidney Week 2026
The findings extend previous research into HTD1801’s potential to address kidney impairment associated with metabolic abnormalities.
-
Mayo Clinic develops nanotherapy to deliver cancer drugs to brain tumors
Researchers used patient-derived tumor tissue to investigate whether the technology could improve drug delivery and make tumors more responsive to treatment.
-
Alameda Healthcare hosts second annual conference to advance medical education in Egypt
Building on its inaugural edition in 2025, the conference expanded its scientific programme to include lectures, clinical case discussions, practical workshops and panel sessions led by Egyptian and international experts.
-
Sidra Medicine opens MENA Microbiome Conference 2026 in Doha
A key announcement was the launch of QMicrobe, a programme designed to establish Qatar’s first dedicated paediatric donor stool bank for therapeutic research.
-
Euromed Study reports skin health benefits of pomegranate extract in Spain
The randomised, triple-blind, placebo-controlled trial enrolled 66 women aged 30 to 65 with hyperpigmented facial spots.
-
Uganda advances two candidate vaccines against Bundibugyo Ebola virus
The trials will advance the evaluation of the two candidates against the Bundibugyo virus, a species distinct from the Zaire Ebola virus targeted by the widely used Ervebo vaccine.
-
Merck advances EyeBio’s Remigromig in US trial for diabetic macular edema
Merck plans to present the BRUNELLO results at the American Academy of Ophthalmology Annual Meeting in New Orleans on October 10 and discuss the findings with regulatory authorities.